Tango Therapeutics (TNGX) Change in Acquisitions & Divestments (2020 - 2026)

Tango Therapeutics' Change in Acquisitions & Divestments history runs 7 years deep, the most recent figure standing at $64.0 million for Q1 2026.

• On a quarterly basis, Change in Acquisitions & Divestments fell 17.69% year-over-year to $64.0 million in Q1 2026; TTM through Mar 2026 was $210.9 million, a 28.84% decrease from a year earlier, with the FY2025 full-year figure at $224.6 million, down 31.46% from the prior year.
• Change in Acquisitions & Divestments improved to $64.0 million in Q1 2026 per TNGX's latest filing, from $39.5 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $109.3 million in Q1 2024 and bottomed at $39.5 million in Q4 2025.
• The 5-year median for Change in Acquisitions & Divestments is $72.1 million (2024), against an average of $71.3 million.
• Across the five-year window, Change in Acquisitions & Divestments surged 106.98% in 2022 and tumbled 53.35% in 2025, its largest moves.
• Year by year, Change in Acquisitions & Divestments stood at $82.0 million in 2022, then increased by 3.79% to $85.1 million in 2023, then retreated by 0.43% to $84.7 million in 2024, then tumbled by 53.35% to $39.5 million in 2025, then surged by 62.04% to $64.0 million in 2026.
• Per Business Quant, the three latest TNGX Change in Acquisitions & Divestments figures stand at $64.0 million (Q1 2026), $39.5 million (Q4 2025), and $66.0 million (Q3 2025).